Capture Vascular, Inc. (Capture) has been ranked as a Top 10 Cardiovascular Device Company of 2018 by Medical Tech Outlook Magazine.

"We couldn't be more elated to be recognized as one of the Top 10 Cardiovascular Device Companies of 2018," stated Eric Wells, CEO of Capture. "The team has been working hard and 2018 is off to a great start. We continue to generate interest in our commercialized PAD-ATK device. We received the CE Mark in February and continue to receive significant international distribution interest. This has definitely been a very exciting year so far," stated Wells.

To add to the momentum, Capture is about to launch its Coronary (CAD) device in September 2018 and anticipates launching its DVT device in Q1 2019.

“Dr. Jeffrey Chambers presented Capture's CAD MegaVac Mechanical Thrombectomy System at SCAI 2018 last month in San Diego, CA. Our focus for the balance of 2018 is to get Capture’s devices in the hands of physicians in order to continue to build the data to support the benefits of using the system. We believe that Vascular Surgeons, Interventional Cardiologists, and Interventional Radiologists around the world will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive treatments,” stated Wells.

For the full list of Top Cardiovascular Device Companies as ranked by Medical Tech Outlook Magazine click here.

Dr. Chambers, interventional cardiologist, presented Capture Vascular at the SCAI 2018 conference in San Diego, CA last week. Watch his full presentation that includes commentary about how the MegaVac Mechanical Thrombectomy System is simple to use and facilitates optimal thrombus removal via the video link below:

Dr. Ramaiah joined the medical staff of Abrazo Arizona Heart Institute and Hospital in 1999 after a year of private practice in vascular surgery at the Eisenhower Medical Center in Rancho Mirage, California. He received his medical degree (MBBS) and Masters in Surgery (MS) from the University of Bombay in India. He is board-certified in general surgery and completed his surgical training at Episcopal Hospital in Philadelphia. Dr. Ramaiah also completed a fellowship in vascular surgery at the Arizona Heart Institute.

Dr. Ramaiah specializes in endovascular and vascular surgery. He treats conditions such as complications with blood vessels and intervenes to prevent aneurysms and heart attacks. Additionally, Dr. Ramaiah conducts endovascular research at the Arizona Heart Institute. He is currently the medical director of the Arizona Heart Hospital. He is also the director of Peripheral and Endovascular Research at the Arizona Heart Institute, and is the principal investigator in numerous research studies and protocols.

He is actively involved in many prestigious medical groups both nationally and internationally, serving as faculty and director, and has also published extensively in numerous journals and text book chapters.

John H. Rundback, MD, is a renowned interventional radiologist in practice for nearly two decades and is the Director of the Interventional Institute at Holy Name Medical Center. He is board-certified in radiology and holds a Certificate of Added Qualification in Angiography and Interventional Radiology. He has been named as a Top Doctor by Castle Connolly.

Dr. Rundback's research interests include peripheral arterial, carotid and aortic aneurysmal disease, deep venous thrombosis and varicose veins, as well as state-of-the art minimally invasive cancer therapies, and he is the principal investigator on a number of multi-center trials. He has presented at more than 200 conferences and is the program chairman for his own peripheral arterial disease symposium. He has served as an editor and reviewer for peer-reviewed medical journals and published over 100 articles.

At Holy Name, Dr. Rundback serves on the Patient Safety Committee, the Cancer Committee, and the Credentialing Committee. Dr. Rundback is a past member of the Board of Directors of the Society of Interventional Radiology Foundation and Founding Chair for the Foundation's Cooperative Alliance for Interventional Research Clinical Trials Network. Dr. Rundback earned his medical degree from SUNY Downstate Medical Center, after which he completed his internship at St. Vincent's Hospital and Medical Center in New York. He completed his diagnostic radiology residency at Beth Israel Medical Center in New York where he also served as chief resident, and completed his fellowship in interventional radiology at Washington Hospital Center in Washington, DC.

Capture Vascular, Inc. (Capture), a Telluride Medical Partners company, announced today that it has received CE (Conformité Européenne) marking for its proprietary MegaVac Mechanical Thrombectomy System.

“The CE mark is a critical milestone for Capture; the team has been working on its issuance since mid-2017,” stated Eric Wells, CEO of Capture. “We can now launch our sales efforts in Europe, a market that has expressed great interest in Capture’s technology,” stated Wells.

Capture is currently in early discussions with a number of European distribution partners, has a few agreements in place, and is working diligently to finalize additional agreements now that the CE mark has been issued.

“We are confident that Vascular Surgeons, Interventional Cardiologists, and Interventional Radiologists throughout Europe will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive peripheral treatments,” stated Wells.

Capture’s proprietary technology includes key features such as centering and securing the occlusion funnel tip position within the vessel and being able to pass other lesion disruptive devices through its lumen.

Founded in 2013, Capture’s proprietary technology includes the MegaVac Catheter with SafeSeal Technology and the ThromboWire Clot Retractor, which makes up the MegaVac Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device. For more information about Capture Vascular and its technology please visit www.capturevascular.com.

Telluride Medical Partners (TMP) announced today that it has secured $2.2 million in new financing that will be invested into TMP’s portfolio of companies.

The new financing comes from two investors and closed at the end of 2017, with a large portion coming from a private individual with a family office in Houston, Texas that invests in energy, real estate and medical, among other industries. The second investment came from Regis Medical, a German company that specializes in the commercialization and distribution of high-quality and innovative medical device products.

“We are excited to have two new investors involved with TMP who both bring their own set of industry connections to help advance TMP and its portfolio of companies,” stated Eric Wells, CEO and Founder of Telluride Medical Partners. “This new funding will go towards the continued development and commercialization of each company’s disruptive medical device technology,” stated Wells.

TMP continues to attract interest from partners and investors alike and the team is focused on further exposing its companies by attending elite industry conferences and networking events.

“We received a great amount of interest from strategic partners and investors from around the world while attending meetings at the recent J.P. Morgan Healthcare Conference in San Francisco,” stated Wells. “As we continue to advance each company it is imperative to stay connected with medical device experts and industry influencers to continue to drive interest and market our companies. We look forward to cultivating these new relationships in the coming weeks,” stated Wells.

TMP’s portfolio of companies is impressive to say the least.

Capture Vascular’s proprietary thrombectomy system, the MegaVacTM Mechanical Thrombectomy System, is a disruptive technology that offers several unique features in one simple device such as centering and securing the occlusion funnel tip position within the vessel, as well as being able to pass other lesion disruptive devices through its lumen. Its unique design and broad indications for use makes it appropriate for several key markets with a total worldwide market opportunity greater than $500M.

Nectero Medical focuses on the development of the disruptive early-stage treatment of abdominal aortic aneurysms (AAA), and has developed a patented compound called pentagalloyl glucose that stabilizes elastin and improves tissue strength that can be used as early treatment for patients living with AAA. Nectero Medical’s potential customers include the currently diagnosed and undiagnosed 1 million people in the US living with AAA between the size of 4.0 and 5.0cm in diameter. Note the US only represents 25.6 percent of the world AAA market.

Chrona Sleep’s proprietary sleep therapy technology applies acoustic neuromodulation to enhance sleep and neuroplasticity, targeting more than 113 million sleep-deprived Americans. The market is expected to experience explosive growth with projections of one billion sleep therapy devices to be sold in 2020.

Lighthill Medical is developing a family of catheters for the delivery of oncology agents for image-guided, minimally invasive interventional procedures. Over 700,000 individuals globally are diagnosed with liver cancer alone every year and 85 percent are non-resectable, which equates to 573,000 individuals who are potential candidates for targeted therapy. This represents a $340M market opportunity.

Nespiro has developed a new data-driven solution for mechanical ventilation weaning and prediction of post-extubation complications utilizing a proprietary open-loop algorithm along with additional sensor inputs across the thoracic cavity. As an accessory product business model, Nespiro’s market is an estimated $192M in the US specific to disposable components alone.

For more information about TMP and its portfolio of companies please visit www.telluridemedicalpartners.com or contact TMP’s CFO, Bryan Ziegler, via email (bziegler@telluridemp.com).

The first case involved a 42-year-old male patient with a target treatment area of the right leg, above and below the knee. Overall the MegaVacTM Mechanical Thrombectomy System was noted that it worked both easy and well and the procedure was marked successful.

The second case involved a 62-year-old female patient with a target treatment area of the left leg above the knee. Again the system was noted as working both easy and well where the procedure was not only successful, but the MegaVacTM Mechanical Thrombectomy System exceeded expectations.

The third case involved a 67-year-old male patient with a target treatment area of the left leg, above and below the knee. The MegaVacTM Catheter and ThromboWireTM Clot Retractor both performed well with debris noted in the ThromboWireTM Clot Retractor after removal.

Capture will continue to perform clinical cases throughout the coming months as it focuses on adoption of the MegaVacTM Mechanical Thrombectomy System-ATK.

The recently expanded device description of the ATK builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel, in addition to being able to pass through other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System-ATK can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“In working through recent clinical experiences we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customer’s needs and execute these device advances,” says Wells.

Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device.

Capture Vascular Inc. (Capture), a Telluride Medical Partners company, announced today that it has received updated FDA 510(k) clearance that expands the device description for its proprietary MegaVacTM Mechanical Thrombectomy System.

“In working through recent clinical experiences, we continually received feedback from physicians that they wanted to use Capture’s system as a proximal occlusion conduit for atherectomy systems, CTO crossing wires, balloons and stents,” says Eric Wells, CEO of Capture Vascular. “I’m particularly excited that the team was able to meet our customers needs and execute these device advances,” says Wells.

The expanded device description builds off of Capture’s mechanical thrombectomy technology with key features such as centering and securing the occlusion funnel tip position within the vessel and being able to pass other lesion disruptive devices through its lumen. With these updates, Capture’s MegaVacTM Mechanical Thrombectomy System can now provide proximal occlusion, a static work environment, and the removal of emboli and thrombi for even more situations.

“We are confident that Vascular Surgeons, Interventional Cardiologists and Interventional Radiologists will find the system effective and easy-to-use in providing proximal occlusion of antegrade blood flow, thereby reducing the potential for an embolic occurrence while performing highly disruptive peripheral treatments,” says Wells.

Founded in 2013, Capture’s proprietary technology includes the MegaVacTM Catheter with SafeSealTM Technology and the ThromboWireTM Clot Retractor, which makes up the MegaVacTM Mechanical Thrombectomy System. With a strong portfolio of 30 patents, Capture’s innovative system offers several unique features in one simple, efficient, and effective device.For more information about Capture Vascular and its technology please visit www.capturevascular.com.